| Jamie G Loschen, AUD | |
|
7850 Vance Dr Ste 225, Arvada, CO 80003-2133 | |
| (303) 431-8881 | |
| (303) 456-8924 |
| Full Name | Jamie G Loschen |
|---|---|
| Gender | Female |
| Speciality | Audiologist-hearing Aid Fitter |
| Location | 7850 Vance Dr Ste 225, Arvada, Colorado |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1568844033 | NPI | - | NPPES |
| 110105823A | Medicaid | MA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 231H00000X | Audiologist | 1070 (Massachusetts) | Secondary |
| 237600000X | Audiologist-hearing Aid Fitter | 906 (Colorado) | Primary |
| Provider Name | Cape Cod Hearing Services Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1033536123 PECOS PAC ID: 4284967001 Enrollment ID: O20190611001775 |
News Archive
In a new revealing report, a Victorian Government official – from the Office of the Public Advocate (OPA), spoke about the declining level of care and protection provided to those with a mental disability. The OPA report entitled "Violence against People with Cognitive Impairments" analyzed 86 cases of abuse in government-funded and private support facilities over four years and reported mistreatment including instances of physical, sexual, psychological, and emotional abuse - sometimes by carers themselves. The report said police often believe the perpetrator of the abuse, rather than the mentally impaired victim.
Just as the emotions it represents are dynamic, the heart's development requires dynamic shifts in proteins that prompt alternative spicing, a mechanism that allows a given gene to program the cell to make several proteins, said a group of researchers at Baylor College of Medicine in a report that appears online in the journal Proceedings of the National Academy of Sciences.
Conatus Pharmaceuticals Inc. announced today the initiation of a Phase II clinical trial evaluating CTS-1027 in combination with pegylated interferon (Pegasys®) and ribavirin (Copegus®) in refractory HCV patients. Antiviral activity, safety and tolerability of the triple combination will be assessed after up to 48 weeks of therapy.
Stem Cell Therapy International, Inc. is proud to announce the execution of the Reorganization and Stock Purchase Agreement ("the Agreement") with Histostem Co., Ltd., a Korean company ("Histostem" and together with SCII, "the parties").
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jamie G Loschen, AUD 7850 Vance Dr Ste 225, Arvada, CO 80003-2133 Ph: (303) 431-8881 | Jamie G Loschen, AUD 7850 Vance Dr Ste 225, Arvada, CO 80003-2133 Ph: (303) 431-8881 |
News Archive
In a new revealing report, a Victorian Government official – from the Office of the Public Advocate (OPA), spoke about the declining level of care and protection provided to those with a mental disability. The OPA report entitled "Violence against People with Cognitive Impairments" analyzed 86 cases of abuse in government-funded and private support facilities over four years and reported mistreatment including instances of physical, sexual, psychological, and emotional abuse - sometimes by carers themselves. The report said police often believe the perpetrator of the abuse, rather than the mentally impaired victim.
Just as the emotions it represents are dynamic, the heart's development requires dynamic shifts in proteins that prompt alternative spicing, a mechanism that allows a given gene to program the cell to make several proteins, said a group of researchers at Baylor College of Medicine in a report that appears online in the journal Proceedings of the National Academy of Sciences.
Conatus Pharmaceuticals Inc. announced today the initiation of a Phase II clinical trial evaluating CTS-1027 in combination with pegylated interferon (Pegasys®) and ribavirin (Copegus®) in refractory HCV patients. Antiviral activity, safety and tolerability of the triple combination will be assessed after up to 48 weeks of therapy.
Stem Cell Therapy International, Inc. is proud to announce the execution of the Reorganization and Stock Purchase Agreement ("the Agreement") with Histostem Co., Ltd., a Korean company ("Histostem" and together with SCII, "the parties").
› Verified 8 days ago